Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
196 Leser
Artikel bewerten:
(0)

Global Type 1 Diabetes Market 2014-2018: Key Vendors are Astrazeneca, Eli Lilly and Co, Novo Nordisk and Sanofi-Aventis

DUBLIN, July 18, 2014 /PRNewswire/ --


Research and Markets(http://www.researchandmarkets.com/research/3txjqf/global_type_1) has announced the addition of the"Global Type 1 Diabetes Market 2014-2018"report to their offering.

Type 1 diabetes is an autoimmune disorder characterized by high blood glucose levels. In this condition, the immune system is activated against self-insulin producing cells. This, in turn, hampers the body's ability to produce insulin and disrupts blood glucose homeostasis. Type 1 diabetes T1D differs from the more common form of diabetes mellitus, Type 2 diabetes, as people with Type 2 diabetes do produce insulin. T1D accounts for only 5-15 percent of the total diabetic cases and is usually reported in children and adolescents. T1D was formerly known as juvenile diabetes. T1D management relies on providing symptomatic relief and improving quality of life.

The analysts forecast the Global Type 1 Diabetes Market will grow at a CAGR of 6.9 percent over the period 2013-2018.

This report covers the present scenario and the growth prospects of the Global Type 1 Diabetes Market for the period 2014-2018. To calculate the market size, the report considers revenue generated from the sales of various type 1 diabetes management drugs, which includes insulin-based replacement products and amylin analogues.

The report, the Global Type 1 Diabetes Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Type 1 Diabetes market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.


Key Topics Covered:

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

04. Market Research Methodology

05. Introduction

06. Market Landscape

07. Global Market Share by Products

08. Product Portfolio

09. Clinical Pipeline Portpolio

10. Geographical Segmentation

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape


Companies Mentioned:

  • Astrazeneca plc
  • Eli Lilly and Co.
  • Novo Nordisk A/S
  • Sanofi-Aventis US LLC
  • Biodel Inc.
  • Diamyd Medical AB
  • DiaVacs Inc.
  • Generex Biotechnology Corp.
  • Lexicon Pharmaceuticals Inc.
  • Macrogenics Inc.
  • MannKind Corp.
  • Osiris Therapeutics Inc.
  • Tolerion Inc.
  • XOMA Corp.


For more information visithttp://www.researchandmarkets.com/research/3txjqf/global_type_1


Media Contact:Laura Wood , +353-1-481-1716, press@researchandmarkets.net


Großer Dividenden-Report 2024 von Dr. Dennis Riedl
Der kostenlose Dividenden-Report zeigt ganz genau, wo Sie in diesem Jahr zuschlagen können. Das sind die Favoriten von Börsenprofi Dr. Dennis Riedl
Jetzt hier klicken
© 2014 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.